Heterodimerized polypeptide

Patent metadata

Field	Value
Publication number	US-9890218-B2
Application number	US-201214127576-A
Country	US
Kind code	B2
Filing date	Jun 29, 2012
Priority date	Jun 30, 2011
Publication date	Feb 13, 2018
Grant date	Feb 13, 2018

Abstract

The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved Fc region function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.

First claim

The invention claimed is:

1. A molecule comprising a heterodimeric Fc region that is a heterodimer of a first polypeptide comprising a first CH2 domain and a second polypeptide comprising a second CH2 domain that differs in amino acid sequence from the first CH2 domain,
wherein the first CH2 domain is an IgG1 CH2 domain comprising a set of amino acid mutations selected from sets (i)-(vi) (all positions by EU numbering):
(i) substitution of L at position 234 with Y,
substitution of L at position 235 with Y,
substitution of G at position 236 with W,
substitution of H at position 268 with D, and
substitution of S at position 298 with A;

(ii) substitution of L at position 234 with Y,
substitution of L at position 235 with Y,
substitution of G at position 236 with W,
substitution of H at position 268 with D,
substitution of D at position 270 with E, and
substitution of S at position 298 with A;

(iii) substitution of L at position 234 with Y,
substitution of L at position 235 with Q,
substitution of G at position 236 with W,
substitution of S at position 239 with M,
substitution of H at position 268 with D,
substitution of D at position 270 with E, and
substitution of S at position 298 with A;

(iv) substitution of L at position 234 with Y,
substitution of L at position 235 with Y,
substitution of G at position 236 with W,
substitution of H at position 268 with D,
substitution of S at position 298 with A, and
substitution of A at position 327 with D;

(v) substitution of L at position 234 with Y,
substitution of L at position 235 with Y,
substitution of G at position 236 with W,
substitution of S at position 239 with M,
substitution of H at position 268 with D,
substitution of S at position 298 with A, and
substitution of A at position 327 with D;

(vi) substitution of L at position 234 with Y,
substitution of L at position 235 with Y,
substitution of G at position 236 with W,
substitution of S at position 239 with M,
substitution of H at position 268 with D,
substitution of S at position 298 with A,
substitution of A at position 327 with D,
substitution of L at position 328 with W, and
substitution of K at position 334 with L;

and the second CH2 domain is an IgG1 CH2 domain comprising a set of amino acid mutations selected from sets (vii)-(ix) (all positions by EU numbering):
(vii) substitution of K at position 326 with D,
substitution of A at position 330 with M, and
substitution of K at position 334 with E;

(viii) substitution of D at position 270 with E,
substitution of K at position 326 with D,
substitution of A at position 330 with M, and
substitution of K at position 334 with E;

(ix) substitution of D at position 270 with E,
substitution of K at position 326 with D,
substitution of A at position 330 with K, and
substitution of K at position 334 with E.

2. The molecule of claim 1 , wherein the amino acid sequences of the first and the second polypeptides differ at one or more other positions in addition to the positions of the set of mutations in the first CH2 domain and the positions of the set of mutations in the second CH2 domain, wherein the differences at the one or more other positions confer or increase a difference in isoelectric points between the first polypeptide and the second polypeptide.

3. The molecule of claim 2 , wherein each of the first and second polypeptides comprises a human IgG1 Fc region with multiple mutations, and wherein the one or more other positions where the first and second polypeptides differ in sequence are selected from the following positions in one or both of the human IgG1 Fc regions (all positions by EU numbering): 137, 138, 139, 147, 192, 193, 196, 198, 199, 203, 214, 263, 272, 274, 278, 288, 290, 316, 317, 320, 324, 335, 337, 340, 358, 360, 362, 364, 383, 384, 385, 386, 387, 390, 397, 422.

4. The molecule of claim 2 , wherein each of the first and second polypeptides comprises a human IgG1 Fc region with multiple mutations, and wherein the one or more other positions where the first and second polypeptides differ in sequence are selected from:
one or more of the following positions in the human IgG1 Fc region of the first polypeptide (all positions by EU numbering): 196, 199, 263, 272, 316, 358, 364, 383, 387, 397; and
one or more of the following positions in the human IgG1 Fc region of the second polypeptide (all positions by EU numbering): 137, 138, 139, 147, 192, 193, 198, 199, 203, 214, 274, 278, 288, 290, 316, 317, 320, 324, 335, 337, 340, 358, 360, 362, 383, 384, 385, 386, 390, 422.

5. The molecule of claim 1 , wherein the molecule is an antibody.

6. The molecule of claim 5 , wherein the antibody is a bispecific antibody.

7. The molecule of claim 1 , wherein the molecule is a peptide Fc fusion protein or a scaffold Fc fusion protein.

8. A pharmaceutical composition comprising the molecule of claim 1 and a medically acceptable carrier.

9. A method of producing the molecule of claim 1 , the method comprising: producing the first polypeptide and the second polypeptide; and generating the molecule comprising a heterodimeric Fc region that is a heterodimer of the first polypeptide and the second polypeptide.

10. The method of claim 9 , further comprising:
assaying a function of the generated molecule, thereby determining that said function of the generated molecule is increased compared to said function of both (a) a dimeric Fc region that is a homodimer of the first polypeptide, and (b) a dimeric Fc region that is a homodimer of the second polypeptide, wherein the function is (i) binding affinity for an Fc receptor, or (ii) selectivity of binding to one type of Fc receptor over another type of Fc receptor.

11. A method of producing the molecule of claim 1 , the method comprising:
identifying a parent molecule comprising an Fc region that is a homodimer of a starting polypeptide;
producing a first mutated version of the starting polypeptide, the first mutated version being the first polypeptide;
producing a second mutated version of the starting polypeptide, the second mutated version being the second polypeptide; and
generating the molecule comprising a heterodimeric Fc region that is a heterodimer of the first polypeptide and the second polypeptide.

12. The method of claim 11 , further comprising:
assaying a function of the generated molecule, thereby determining that said function of the generated molecule is increased (a) compared to said function of a dimeric Fc region that is a homodimer of the first polypeptide, and (b) compared to said function of a dimeric Fc region that is a homodimer of the second polypeptide, wherein the function is (i) binding affinity for an Fc receptor, or (ii) selectivity of binding to one type of Fc receptor over another type of Fc receptor.

13. The molecule of claim 1 , wherein the first CH2 domain comprises the mutations of set (i).

14. The molecule of claim 1 , wherein the first CH2 domain comprises the mutations of set (ii).

15. The molecule of claim 1 , wherein the first CH2 domain comprises the mutations of set (iii).

16. The molecule of claim 1 , wherein the first CH2 domain comprises the mutations of set (iv).

17. The molecule of claim 1 , wherein the first CH2 domain comprises the mutations of set (v).

18. The molecule of claim 1 , wherein the first CH2 domain comprises the mutations of set (vi).

19. The molecule of claim 1 , wherein the second CH2 domain comprises the mutations of set (vii).

20. The molecule of claim 1

Assignees

• Mimoto Futa
• Kuramochi Taichi
• Igawa Tomoyuki
• Kawazoe Meiri
• Katada Hitoshi
• Shiraiwa Hirotake
• Kadono Shojiro
• Chugai Pharmaceutical Co Ltd

Inventors

• Mimoto Futa
• Kuramochi Taichi
• Igawa Tomoyuki
• Kawazoe Meiri
• Katada Hitoshi
• Shiraiwa Hirotake
• Kadono Shojiro

Classifications

• G01N33/566

  using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds} · CPC title

• C07K16/46 Primary

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title

• C07K16/36

  against blood coagulation factors · CPC title

• C07K16/303

  Liver or Pancreas · CPC title

• C07K16/30

  from tumour cells · CPC title